ES2147754T3 - Inactivacion selectiva de celulas en sangre. - Google Patents

Inactivacion selectiva de celulas en sangre.

Info

Publication number
ES2147754T3
ES2147754T3 ES93909729T ES93909729T ES2147754T3 ES 2147754 T3 ES2147754 T3 ES 2147754T3 ES 93909729 T ES93909729 T ES 93909729T ES 93909729 T ES93909729 T ES 93909729T ES 2147754 T3 ES2147754 T3 ES 2147754T3
Authority
ES
Spain
Prior art keywords
blood
cells
treatment
high levels
selective inactivation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93909729T
Other languages
English (en)
Inventor
Janice North
Julia Levy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Novelion Therapeutics Inc
Original Assignee
University of British Columbia
QLT Phototherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, QLT Phototherapeutics Inc filed Critical University of British Columbia
Application granted granted Critical
Publication of ES2147754T3 publication Critical patent/ES2147754T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EL TRATAMIENTO CON UN CONJUNTO DE COMPUESTOS DE PORFIRINA, USANDO PROCEDIMIENTO DE TERAPIA FOTODINAMICA, ES CAPAS DE, SELECTIVAMENTE, REDUCIR NIVELES ELEVADOS DE LEUCOCITOS ACTIVADOS EN UNA POBLACION DE LEUCOCITOS. MEDIANTE EL USO DE TALES COMPUESTOS, CON ABSORCION MAXIMA DE 670 NM O SUPERIOR, LAS LONGITUDES DE ONDA DE IRRADIACION PUEDEN SELECCIONARSE, PARA PERMITIR EL TRATAMIENTO DE TEJIDOS COMPLEJOS, TALES COMO LA SANGRE TOTAL. ESTO RESULTA ESPECIALMENTE UTIL EN PERSONAS QUE CONTIENEN TALES NIVELES ELEVADOS DE SUBCONJUNTOS DE CELULAS T, TALES COMO PERSONAS INFECTADAS DE HIV.
ES93909729T 1992-05-27 1993-05-27 Inactivacion selectiva de celulas en sangre. Expired - Lifetime ES2147754T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/889,707 US5776966A (en) 1992-05-27 1992-05-27 Selective cell inactivation in blood

Publications (1)

Publication Number Publication Date
ES2147754T3 true ES2147754T3 (es) 2000-10-01

Family

ID=25395640

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93909729T Expired - Lifetime ES2147754T3 (es) 1992-05-27 1993-05-27 Inactivacion selectiva de celulas en sangre.

Country Status (23)

Country Link
US (1) US5776966A (es)
EP (1) EP0642342B1 (es)
JP (1) JP3174821B2 (es)
KR (1) KR950701522A (es)
AT (1) ATE194491T1 (es)
AU (1) AU687734B2 (es)
CA (1) CA2136447C (es)
CZ (1) CZ283846B6 (es)
DE (1) DE69329026T2 (es)
DK (1) DK0642342T3 (es)
ES (1) ES2147754T3 (es)
FI (1) FI945586L (es)
GR (1) GR3034529T3 (es)
HU (1) HUT78021A (es)
IL (1) IL105815A (es)
MX (1) MX9303127A (es)
NO (1) NO308506B1 (es)
NZ (1) NZ252085A (es)
PT (1) PT642342E (es)
SK (1) SK143994A3 (es)
TW (1) TW257674B (es)
WO (1) WO1993024127A1 (es)
ZA (1) ZA933723B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807881A (en) * 1992-05-27 1998-09-15 Quadra Logic Technologies, Inc. Method for selectively reducing activated leukocyte cell population
US5756541A (en) 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
CA2221912A1 (en) * 1997-11-21 1999-05-21 David Dolphin Photosensitizers with improved biodistribution and light-absorbing properties
US6117862A (en) 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
WO2000041726A2 (en) 1999-01-15 2000-07-20 Light Sciences Corporation Noninvasive vascular therapy
US6454789B1 (en) 1999-01-15 2002-09-24 Light Science Corporation Patient portable device for photodynamic therapy
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
US7022843B1 (en) 1999-04-14 2006-04-04 The University Of British Columbia β,β′-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US6734192B1 (en) 1999-08-23 2004-05-11 Mp-1 Inc. Treatment of viral infections
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US8106038B2 (en) 2001-02-15 2012-01-31 Qlt Inc. Method for reducing or preventing PDT related inflammation
US7498029B2 (en) 2001-05-01 2009-03-03 The General Hospital Corporation Photoimmunotherapies for cancer using combination therapies
WO2003003975A2 (en) * 2001-06-04 2003-01-16 The General Hospital Corporation Detection and therapy of vulnerable plaque with photodynamic compounds
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
EP1539929B1 (en) * 2002-06-28 2013-04-10 Life Technologies Corporation Methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US7220778B2 (en) * 2003-04-15 2007-05-22 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
US7659301B2 (en) * 2003-04-15 2010-02-09 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
KR100604350B1 (ko) 2004-07-15 2006-07-25 학교법인 인제학원 광역학 치료용 광민감성 물질로 유용한 사이클릭테트라피롤 고분자와 이의 제조방법
ES2454974T3 (es) * 2007-06-27 2014-04-14 The General Hospital Corporation Aparato para la inhibición óptica de la terapia fotodinámica
PL233504B1 (pl) 2014-05-09 2019-10-31 Univ Jagiellonski Protoporfiryna IX kobaltu do stosowania w leczeniu neutropenii i białaczek
US10328085B2 (en) 2014-05-09 2019-06-25 Uniwersytet Jagiellonski Cobalt porphyrins for the treatment of blood-related disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4610241A (en) * 1984-07-03 1986-09-09 Gordon Robert T Atherosclerosis treatment method
US5011684A (en) 1985-09-05 1991-04-30 Beth Israel Hospital Association Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US5171749A (en) * 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
DE3821254A1 (de) 1988-06-23 1990-01-04 Hoffmann Elektrokohle Schleifstueck fuer stromabnehmer sowie verfahren zu seiner herstellung
US5190966A (en) * 1988-07-06 1993-03-02 Health Research, Inc. Purified hematoporphyrin dimers and trimers useful in photodynamic therapy
US5028594A (en) * 1988-12-27 1991-07-02 Naxcor Use of photodynamic compositions for cytotoxic effects
US4960408A (en) * 1989-01-10 1990-10-02 Klainer Albert S Treatment methods and vaccines for stimulating an immunological response against retroviruses
US5149708A (en) * 1989-06-07 1992-09-22 University Of British Columbia Photosensitizing Diels-Alder porphyrin derivatives
US5087636A (en) * 1990-02-20 1992-02-11 University Of British Columbia Method to destroy malignant cells in mononuclear cell populations
US5214036A (en) * 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy

Also Published As

Publication number Publication date
KR950701522A (ko) 1995-04-28
IL105815A (en) 2000-01-31
GR3034529T3 (en) 2000-12-29
FI945586A7 (fi) 1995-01-27
HU9403385D0 (en) 1995-02-28
NO944537D0 (no) 1994-11-25
AU687734B2 (en) 1998-03-05
NO944537L (no) 1995-01-20
SK143994A3 (en) 1996-07-03
MX9303127A (es) 1994-06-30
CA2136447C (en) 2001-06-19
IL105815A0 (en) 1993-09-22
FI945586A0 (fi) 1994-11-28
JPH08501278A (ja) 1996-02-13
CZ283846B6 (cs) 1998-06-17
JP3174821B2 (ja) 2001-06-11
DK0642342T3 (da) 2000-10-09
DE69329026D1 (de) 2000-08-17
NZ252085A (en) 1998-02-26
CA2136447A1 (en) 1993-12-09
US5776966A (en) 1998-07-07
HUT78021A (hu) 1999-05-28
WO1993024127A1 (en) 1993-12-09
ZA933723B (en) 1993-12-15
NO308506B1 (no) 2000-09-25
FI945586L (fi) 1995-01-27
CZ291894A3 (en) 1995-09-13
EP0642342B1 (en) 2000-07-12
TW257674B (es) 1995-09-21
EP0642342A1 (en) 1995-03-15
PT642342E (pt) 2000-11-30
AU4057193A (en) 1993-12-30
DE69329026T2 (de) 2001-03-22
ATE194491T1 (de) 2000-07-15

Similar Documents

Publication Publication Date Title
ES2147754T3 (es) Inactivacion selectiva de celulas en sangre.
US7084389B2 (en) Hand held led device
NZ292854A (en) Use of an photoactive compound to treat multiple sclerosis which is followed by light therapy
ES2022886B3 (es) Conjunto de dispositivos luminosos para un sistema de tratamiento de pacientes por fotoactivacion.
ATE133418T1 (de) Zusammensetzungen zum erreichen eines lasereffektes und methoden zu deren gebrauch
DE69424566D1 (de) Enthaarung
ES2115727T3 (es) Esponja para la cornea.
ATE151984T1 (de) Liposomen mit porphyrin-photosensibilisatoren enthaltende mittel
PT1267931E (pt) Derivados de rodamina para o diagnostico e tratamento fotodinamicos
DK0768886T3 (da) Endothelforingseffekter og behandling af vasospastiske lidelser
DK0671909T3 (da) Syndecanstimulering af cellulær differentiering
ZA871411B (en) Irradiation chamber for photoactivation patient treatment system
ES2077698T3 (es) Agente terapeutico para la gangrena diabetica.
BR8907385A (pt) Preparado com atividade de anticorpo e amplo espectro de acao,agentes consistindo nele ou contendo-o e seu uso para o tratamento de doencas relacionadas com bacterias ou toxinas e para o combate de protozoarios
ATE309808T1 (de) Ex vivo behandlung von allogenen und xenogenen t- zellen mit gp39-antagonisten
ATE247468T1 (de) Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten
JPH05212131A (ja) レーザ治療装置
CN2407779Y (zh) 激光外照射治疗罩
RU92000934A (ru) Световод для облучения биообъектов
MX9703975A (es) Nueva formulacion antitrombotica, proceso para su fabricacion y uso de la misma.
RU94005179A (ru) Средство для лечения больных очаговой склеродермией

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 642342

Country of ref document: ES